Atopic Dermatitis

The ongoing Canadian wildfires are causing poor air quality in the US, which will likely result in more patients seeking help for skin conditions.

Sanofi’s investigational anti-OX40-ligand monoclonal antibody showed statistically significant improvement in signs and symptoms of AD in adults.

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.

A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.

Four clinicians discuss the widening landscape of systemic therapies for patients with atopic dermatitis.

Four dermatologists from across the country discuss the widened armamentarium of AD treatments in a recent Around the Practice series.

Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.

Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.

The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics

The new technique analyzes RNA from infant sebum samples.

Experts in dermatology review recommendations for systemic therapies and JAK inhibitors in the management of AD and other factors that guide treatment selection.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, discuss their initial impressions of an adolescent patient with AD, focusing on systemic therapy.

Del Rosso and Stein Gold will discuss topical management in an in-depth seminar.

Considering the whole patient is crucial in understanding how natural alternatives can improve the skin.

Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, highlight treatment options for a specific patient with AD, focusing on dupilumab.

Experts in dermatology review clinical trials for AD treatment and how this data translates into their own practices.

Expert dermatologists review the use of dupilumab for the treatment of AD, focusing on the once-monthly shot as a factor in selection.

Elizabeth Swanson, MD, and Brad Glick, DO, MPH, FAOCD, share treatment approaches for pediatric patients with AD.

Topline results for the topical sodium channel blocker are expected in 2024.

Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.

A poster presentation from SCALE 2023 evaluated the use of ceramide-containing skin care products with prescription treatments for a healthy skin barrier.

A plethora of oral and topical treatments are available for patients, according to Stein Gold’s SCALE 2023 sessions.

B244 demonstrated significant levels of efficacy in patients with mild-to-severe atopic dermatitis and itch.

Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Del Rosso previews his upcoming sessions at SCALE 2023 discussing the latest updates in management and treatment techniques.

New data from Dermavant showed high levels of efficacy and statistical significance for the topical cream, which is expected to have an sNDA on file with the US FDA in early 2024.

Researchers linked proximity to heavy traffic roadways and risk of atopic dermatitis.